Molecular Weight: 547.58 Doxazosin, a quinazoline-derivative, selectively antagonizes postsynaptic α1-adrenergic receptors, used in the treatment of high blood pressure and urinary retention associated with benign prostatic hyperplasia.
Doxazosin-induced Apoptosis is blocked by specific caspase-8 Inhibitors,
supporting the functional involvement of caspase-8 in doxazosin-induced
apoptosis. Doxazosin increases FADD recruitment and subsequent
caspase-8 activation, implicating Fas-mediated apoptosis as the
underlying mechanism of the effect of Doxazosin in prostate cells. Doxazosin and cholestyramine similarly decreases plasma total and LDL
plus VLDL cholesterols, and total triglycerides on average by 46%, 61%
and 45% respectively. Doxazosin induces DNA Damage and
cell death in HL-1 cell line. Doxazosin treatment decreases cell
viability in primary cultures of neonatal rat cardiomyocytes, and
Hoechst dye vital staining demonstrates doxazosin-induced apoptosis in
primary cultures of human adult cardiomyocytes.
antagonizes the VEGF-mediated angiogenic response of HUVEC cells, by
abrogating cell adhesion to fibronectin and collagen-coated surfaces and
inhibiting cell migration, via a potential downregulation of VEGF
Doxazosin also reduces mean arterial pressure by 18% without affecting heart rate in all hamsters. Doxazosin causes a significant reduction in the wet weight of BabeTGF-beta 1-infected mouse prostate reconstitution (MPR).
Contact us if you need more details on 77883-43-3. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Doxazosin Mesylate 77883-43-3、77883-43-3 Doxazosin Mesylate. If these products fail to match your need, please contact us and we would like to provide relevant information.
Premium Related Products